| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00535-010-0367-5 |
| P698 | PubMed publication ID | 21246383 |
| P2093 | author name string | Akihiro Tamori | |
| Masaru Enomoto | |||
| Norifumi Kawada | |||
| Shigeyuki Wakitani | |||
| Tatsuya Nakatani | |||
| Masayuki Hino | |||
| Masaaki Inaba | |||
| Tatsuya Koike | |||
| Masahiro Tada | |||
| Hitoshi Goto | |||
| Hiroyasu Morikawa | |||
| P2860 | cites work | Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. | Q37715895 |
| A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army | Q40797808 | ||
| COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma | Q41824086 | ||
| Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. | Q43062340 | ||
| Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. | Q43202400 | ||
| Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy | Q43268379 | ||
| Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients | Q43288379 | ||
| Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy | Q43629454 | ||
| Chronic viral hepatitis and TNF-alpha blockade | Q44758379 | ||
| Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial | Q44985061 | ||
| Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients | Q45374140 | ||
| Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate | Q45398031 | ||
| Tumor necrosis factor alpha inhibits the suppressive effect of regulatory T cells on the hepatitis B virus-specific immune response | Q45401519 | ||
| Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis | Q45640054 | ||
| Differentiation of hepatitis B virus genotypes D and E by ELISA using monoclonal antibodies to epitopes on the preS2-region product | Q45741977 | ||
| A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. | Q46981468 | ||
| British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). | Q51853711 | ||
| Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy | Q79871757 | ||
| Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis | Q84729554 | ||
| Chronic hepatitis B: update 2009 | Q29617409 | ||
| Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient | Q32067920 | ||
| Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease | Q32086267 | ||
| Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety | Q33328963 | ||
| Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes | Q34471459 | ||
| Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. | Q34500537 | ||
| Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy | Q35072187 | ||
| Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis | Q35596827 | ||
| Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies | Q35637506 | ||
| Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. | Q36382269 | ||
| Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention | Q36544025 | ||
| Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy | Q36694864 | ||
| Prophylaxis and treatment of hepatitis B in immunocompromised patients | Q36768889 | ||
| The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting | Q37059972 | ||
| Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy | Q37124256 | ||
| Relationship between T-lymphocyte cytokine levels and sero-response to hepatitis B vaccines | Q37277444 | ||
| Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity | Q37347655 | ||
| Natural history of chronic hepatitis B virus infection and long-term outcome under treatment | Q37389943 | ||
| Reactivation of hepatitis B. | Q37462566 | ||
| Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma | Q37526652 | ||
| Effect of etanercept and entecavil in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature | Q37671701 | ||
| P433 | issue | 4 | |
| P921 | main subject | Hepatitis B virus | Q6844 |
| hepatitis B | Q6853 | ||
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 556-564 | |
| P577 | publication date | 2011-01-19 | |
| P1433 | published in | Journal of Gastroenterology | Q15764399 |
| P1476 | title | Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts | |
| P478 | volume | 46 |
| Q34500921 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis |
| Q57245378 | 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis |
| Q37970447 | Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management |
| Q45325449 | Assessing risk of liver enzyme elevation in patients with immune-mediated diseases and different hepatitis B virus serostatus receiving anti-TNF agents: a nested case-control study |
| Q27006996 | Clinical impact of occult hepatitis B virus infection in immunosuppressed patients |
| Q37305100 | Current antiviral practice and course of Hepatitis B virus infection in inflammatory arthritis: a multicentric observational study (A + HBV study). |
| Q54984291 | Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study. |
| Q38544189 | Emerging challenges in managing hepatitis B in HIV patients |
| Q46242353 | Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease |
| Q38239127 | HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. |
| Q40633899 | HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea |
| Q28076703 | Hepatitis B Reactivation During Immunosuppressive Therapy or Cancer Chemotherapy, Management, and Prevention: A Comprehensive Review-Screened |
| Q37291847 | Hepatitis B Serology in Patients with Rheumatic Diseases |
| Q38408897 | Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy |
| Q38094015 | Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis |
| Q35567748 | Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure |
| Q26784247 | Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations |
| Q39995730 | Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification. |
| Q55487854 | Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review. |
| Q38155954 | Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs |
| Q37049118 | Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: A hidden threat |
| Q45359495 | Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases |
| Q42959718 | Hepatitis B virus reactivation induced by infliximab administration in a patient with Crohn's disease |
| Q37655919 | Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy--a report of long-term follow-up of serial cases and literature review |
| Q90648680 | INASL Guidelines on Management of Hepatitis B Virus Infection in Patients receiving Chemotherapy, Biologicals, Immunosupressants, or Corticosteroids |
| Q38335718 | Infection risk associated with anti-TNF-α agents: a review |
| Q85610818 | Involvement of the liver in rheumatic diseases |
| Q92661492 | Isolated Anti-HBc: Significance and Management |
| Q42244740 | JSH Guidelines for the Management of Hepatitis B Virus Infection |
| Q38084250 | Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases |
| Q40810286 | Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. |
| Q38807875 | Occult HBV infection in the oncohematological setting |
| Q35610251 | Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs |
| Q38688782 | Prevention and management of hepatitis B virus reactivation in cancer patients |
| Q40830395 | Prevention of HBV reactivation in patients treated with biologic agents. |
| Q45356997 | Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy |
| Q42224704 | Prospective long-term study of hepatitis B virus reactivation in patients with hematologic malignancy |
| Q46162379 | Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs |
| Q37601987 | Ramsay hunt syndrome in a patient with rheumatoid arthritis after treatment with infliximab |
| Q42227093 | Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs |
| Q90608529 | Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations |
| Q38634826 | Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention |
| Q45252016 | Rheumatology meets hepatology in 2012: a clinician's guideline for TNF inhibitors in hepatitis B/C virus carriers |
| Q38611674 | Risk of Hepatitis B Reactivation in Inflammatory Arthritis Patients Receiving Disease Modifying Anti-Rheumatic Drugs (DMARDs): a Systematic Review and Meta-analysis |
| Q89397558 | Risk of Hepatitis B Reactivation in Patients with Psoriasis on Ustekinumab |
| Q35237316 | Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs. |
| Q40336301 | Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection |
| Q41526311 | Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. |
| Q28084305 | Treatment of rheumatic diseases and hepatitis B virus coinfection |
| Q36302689 | Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model |
| Q50190669 | Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance |
| Q44464843 | Use of biological disease-modifying anti-rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B. |
Search more.